Today's session generated a bearish divergence on CCI. I am still bullish, but always ready for a trend retracement on the 20 EMA Line. Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling any stock you should do your own...
Ichimoku Clouds still confirm the bullish setup. Today's session will be important, if positive, to manifest further bullish intentions (Break of the $92.10 resistance). Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties. Before buying or selling...
If you like this idea, don't forget to support it clicking the Like Button! Positive session for Nasdaq Healthcare that gained 0.39%. However, I still see the possibility of a retracement over the basis of the Bollinger Bands indicator (orange crosses). I was waiting with anxiety today's session to check for a signal of retracement, and it comes with the third...
After a press release indicating that CVS Health plans to open 600 new Health Hub stores this year, CVS stock has once again been climbing. I suspect the breakout will continue once CVS pushes through some resistance. I'm looking for maybe $78 per share from this run. CVS's forward P/E of about 10.5 is very attractive for a stock with large growth prospects in the...
Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance). The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm...
After the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock. The current price is...
Good session for the Nasdaq Healthcare Index, that closed the day with a 1.30% gain. Bullish sentiment is still driving trades. However next session could be characterized by a retracement around the basis of the Bollinger Bands indicator (orange crosses). This is a daily analysis. Disclosure: My ideas contain statements and projections based on assumptions on...
If you like this idea, don't forget to hit the Like Button! After the rally that started at the beginning of October, the Nasdaq Healthcare Index trend is still defined, and it is approaching a new phase after a short term retracement. Values above the Ichimoku Green Cloud confirm bullish power. Next days' trading sessions will be useful to understand if IXHC...
If you like this idea, don't forget to hit the Like Button! Alexion business depends on patent-protected therapies in ultrarare and rare diseases of high unmet medical needs. While competitors are entering the market with biosimilars, Alexion still maintains an essential share of the market. My long term view is bullish. However, from a technical point of view,...
Big news from Bayer and Dare today . Next thing to watch is for FDA approval and then if/when commercialization begins. Until then I think it's still very speculative. HOWEVER. important to note the chart. Last time it traded this high, it remained the case for a few weeks and then plummeted back down to earth. The last time it consistently traded around this...
Women's healthcare company - Lots of upcoming catalysts through 2020. New acquisition this week of Microchips. Could see this fall to .50s if earnings are garbage - which is definitely a possibility, but target is still $2-$3 next year. This is speculative, but I will hold 5k shares from .79 avg.
Intuitive Surgical produces robotic-assisted surgical systems. Currently, the company holds a significant market share in urology and gynecology areas. However, the business model is predicted to expand to other areas such as thoracic, colorectal, and other general soft tissue procedures. From a technical point of view, the stock recovered the highs registered in...
After the stock price touched new highs in October 2019 ( management confirmed rebooting of aducanumab's development), Biogen started a consolidation phase. I plotted the Ichimoku Cloud on a daily chart, together with the Bollinger bands, to highlight the volatility and confirm the consolidation phase. Currently, from a technical point of view, we are in an...
The weekly chart for Mylan has broken out from a bearish trendline this week. We can see from the VPVR that there is not much volume resistance at these prices either. There is also a bullish divergence on the RSI. Relative strength has begun to improve too. The price still needs to clear both a 50-EMA & 200-EMA & bulls would want to see a golden cross occur in...
HIIQ was already undervalued, with a forward P/E of 4.65, but it just got even moreso today as analysts bumped its earnings forecast by roughly 20%. This is a low-volume stock, so the market hasn't yet noticed or reacted to the upgrade except for a few options traders. The main problem with HIIQ is that health insurance stocks face a lot of political risk going...
CVS has been on a monster run, and today it breached the top of its long-term downward trending parallel channel. CVS is overbought, so it will probably pull back before moving higher, but the channel breach is a bullish signal that strongly suggests the downtrend is over. I expect CVS to see 100 within a year or two.
Go Long, Cup and Handle forming on Cigna Corp $CI Worth adding to watchlist and buy on the breakout.
I might be jumping the gun here. Based on Elliot wave forecast, IF Wave 1 and 2 completed, i might be looking at 1.618 - $0.22 target. A break below 0.063 invalidates this outlook and taking shorts at $0.043.